Actionable news
All posts from Actionable news
Actionable news in OCRX: Ocera Therapeutics, Inc.,

Ocera Therapeutics Rises on Positive Phase 1 Results

Ocera Therapeutics Inc. (NASDAQ: OCRX) was breaking out in Tuesday’s session following positive results from a clinical study. The biopharma company announced positive results from its Phase 1 study of the oral formulation of OCR-002, ornithine phenylacetate, in healthy subjects. OCR-002 exhibited encouraging extended-release properties, demonstrated a desirable pharmacokinetic (PK) profile and was well-tolerated.

For some background: OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant...